


# PRODUCT INFORMATION



## Adomeglivant

Item No. 29668

**CAS Registry No.:** 1488363-78-5  
**Formal Name:** N-[4-[(1S)-1-[[4'-(1,1-dimethylethyl)-2,6-dimethyl[1,1'-biphenyl]-4-yl]oxy]-4,4,4-trifluorobutyl]benzoyl]-β-alanine  
**Synonym:** LY2409021  
**MF:** C<sub>32</sub>H<sub>36</sub>F<sub>3</sub>NO<sub>4</sub>  
**FW:** 555.6  
**Purity:** ≥98%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Adomeglivant is supplied as a solid. A stock solution may be made by dissolving the adomeglivant in the solvent of choice, which should be purged with an inert gas. Adomeglivant is soluble in the organic solvent DMSO.

### Description

Adomeglivant is an allosteric antagonist of the glucagon receptor.<sup>1,2</sup> It inhibits glucagon-induced increases in cAMP levels in HEK293 cells expressing the rat glucagon or GLP-1 receptors (IC<sub>50</sub>s = 1.8 and 1.2 μM, respectively) but has no effect on cAMP levels when used alone.<sup>2</sup> Adomeglivant also inhibits increases in cAMP levels induced by GLP-1 or exendin-4 (48-86) amide (Item No. 11096) in HEK293 cells expressing the GLP-1 receptor (IC<sub>50</sub>s = 7 and 12 μM, respectively). It decreases glucose-stimulated insulin secretion when used at a concentration of 1 μM in combination with the GLP-1 receptor antagonist exendin (9-39) in isolated human islets but not glucose-stimulated glucagon secretion when used alone or in combination with exendin (9-39) in isolated mouse islets.<sup>3</sup>

### References

- Li, Y., Ye, Z., Bellman, T.M., *et al.* Efficient synthesis of β-CF<sub>3</sub>/SCF<sub>3</sub>-substituted carbonyls via copper-catalyzed electrophilic ring-opening cross-coupling of cyclopropanols. *Org. Lett.* **17**(9), 2186-2189 (2015).
- Chepurny, O.G., Matsoukas, M.-T., Liapakis, G., *et al.* Non-conventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. *J. Biol. Chem.* **294**(10), 3514-3531 (2019).
- Zhu, L., Dattaroy, D., Pham, J., *et al.* Intra-islet glucagon signaling is critical for maintaining glucose homeostasis. *JCI Insight* **4**(10), e127994 (2019).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/29/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM